Welcome to our dedicated page for KRTL HOLDING GROUP news (Ticker: KRTL), a resource for investors and traders seeking the latest updates and insights on KRTL HOLDING GROUP stock.
KRTL Holding Group Inc. (KRTL) provides essential updates on pharmaceutical compliance, FDA-registered API distribution, and global healthcare partnerships. This page aggregates official announcements and strategic developments from KRTL's subsidiaries and international alliances.
Investors and industry professionals will find verified updates on regulatory milestones, supply chain innovations, and market expansion efforts. Track KRTL's progress in bridging international pharmaceutical standards with U.S. compliance requirements through its specialized divisions.
Key updates include FDA registration achievements, strategic acquisitions in pharmaceutical manufacturing, cosmetic formulation developments, and partnership expansions across global healthcare networks. Content is curated to support informed analysis of KRTL's role in pharmaceutical supply chain resilience.
Bookmark this page for consolidated access to KRTL's corporate announcements, financial disclosures, and operational updates. Regularly updated to reflect the company's evolving position in pharmaceutical compliance and international distribution.
KRTL Holding Group has announced the acquisition of Neurogen Brain Balancing, a California-based neurotechnology company specializing in brain balancing therapies and cognitive optimization systems. The acquisition involves KRTL obtaining 100% of Neurogen's equity through a stock-based structure with a profit-sharing agreement.
The deal positions Neurogen as a KRTL subsidiary, integrating advanced neurotechnology into KRTL's ecosystem. Neurogen's technology offers non-opioid, non-invasive treatment options for cognitive enhancement, stress reduction, and post-trauma recovery. The integration process includes brand alignment, financial system harmonization, and operational planning, supported by KRTL's Quality Management System and Enterprise Resource Planning infrastructure.
As part of the strategic integration, Neurogen will participate in real-world data research through connection with Centro de Investigaciones Químicas - CIQ S.R.L in Bolivia, contributing to global product validation efforts.
KRTL Holding Group (OTC: KRTL) has announced that its subsidiary KRTL Biotech Inc. has signed a Memorandum of Understanding (MOU) with Bolivia's Industria Químico Farmacéutica Sigma Corp for a strategic international merger. The agreement includes shared governance structure and consolidated financial oversight, with Sigma maintaining operational autonomy in Bolivia.
Key terms include Sigma receiving one Special 2021 Series A Preferred Share in KRTL Holding Group and board representation. Financial integration will be managed through SIGMARTL Corp, a U.S.-based entity. The merger aims to integrate Sigma's manufacturing operations and revenue streams into KRTL Biotech, facilitating U.S. market entry for Sigma's pharmaceutical products.
Sigma currently generates annual revenues exceeding $20 million, with facilities operating at 40% capacity. The merged entity projects potential revenue doubling within two years post-integration. The deal is expected to enhance operational efficiency and expand KRTL's presence in international pharmaceutical production.
KRTL Holding Group (OTC: KRTL) has announced a strategic expansion in Bolivia through a joint venture between its subsidiaries, KRTL Biotech and KRTL International, and Centro de Investigaciones Químicas (CIQ). Each subsidiary secured a 9.99% stake in 3451.5 acres of land in the Amazon region, totaling 689.9 acres.
The partnership aims to establish sustainable API extraction, research, and manufacturing facilities in Bolivia, with three key facilities planned in Quillacollo, Santa Cruz, and Cochabamba. CIQ, led by Dr. Bascope, specializes in extracting high-value botanical ingredients from Bolivia's diverse ecosystems.
Through this venture, KRTL Biotech will introduce CIQ's products, including cosmetics, raw materials, minerals, and APIs, to the U.S. market following FDA registration requirements. The collaboration also provides access to CIQ's exotic molecule library for potential pharmaceutical applications in pain management, anti-inflammatory treatments, and dermatology.
KRTL Holding Group has announced the successful FDA registration of Industria Químico Farmaceutica SIGMA CORP (SIGMA), a Bolivian pharmaceutical company, obtaining their Federal Establishment Identifier (FEI). This milestone enables access to the U.S. market and highlights the partnership between KRTL and SIGMA in advancing regulatory readiness.
The collaboration aims to leverage Bolivia's rich biodiversity and natural resources in the pharmaceutical sector. According to the U.S. Department of Commerce, Bolivia presents untapped potential in pharmaceutical manufacturing and export capabilities. The FDA registration demonstrates both companies' commitment to regulatory excellence and quality manufacturing, positioning Bolivian-manufactured pharmaceuticals for global market opportunities.
KRTL Biotech Inc., a wholly owned subsidiary of KRTL Holding Group Inc. (OTC: KRTL), has acquired a 55% majority stake in Skidmore Companies , now rebranded as Nutrivance Global. The acquisition leverages KRTL's Active Pharmaceutical Ingredients (APIs) portfolio with Nutrivance Global's established government and private distribution networks.
The deal includes a sophisticated data platform for real-world decision-making, enhancing distribution efficiency and partner insights. The partnership aims to expand distribution of KRTL's APIs, FDA-approved food and beverage products, and cosmetic lines internationally. A revenue-sharing structure has been implemented to ensure transparent management and accelerate market reach.
The collaboration combines Nutrivance Global's distribution expertise and regulatory compliance capabilities with KRTL's product portfolio, positioning both companies to address growing global demand for APIs and advanced solutions.
KRTL Holding Group's subsidiary, KRTL Biotech, has successfully registered SIGMACORP with the FDA as a U.S. pharmaceutical manufacturer. Acting as SIGMACORP's U.S. Registered Agent, KRTL Biotech aims to facilitate international pharmaceutical integration and diversify the U.S. healthcare supply chain.
This registration enables SIGMACORP to manufacture pharmaceutical products for the U.S. market, potentially introducing more affordable healthcare solutions. The partnership focuses on expanding market opportunities, enhancing competitive advantages, and supporting U.S. healthcare resilience through supply chain diversification.
The milestone strengthens U.S.-Bolivia relations in the healthcare sector and positions KRTL Biotech as a leader in international pharmaceutical collaboration.
KRTL Biotech, a subsidiary of KRTL Holding Group (OTC: KRTL), has achieved FDA registration, marking a strategic milestone in strengthening the U.S. pharmaceutical supply chain. The registration positions KRTL to facilitate international manufacturers' entry into the U.S. market, focusing on delivering high-quality active pharmaceutical ingredients (APIs) and finished products. The company plans to establish a manufacturing and distribution facility in 2025 to support both domestic and international partners. This initiative aims to provide lower-cost alternatives and optimized logistics solutions, enhancing supply chain stability while generating cost savings for the healthcare sector.
KRTL Holding Group, Inc. (OTC: KRTL) has announced a memorandum of understanding (MOU) with Yuhan Care, a subsidiary of the esteemed Yuhan Corporation. This collaboration focuses on developing CBD and cannabinoid-based products aimed at both the US and Korean markets. The agreement leverages KRTL’s established manufacturing partners and Yuhan’s expertise in cannabinoid research, promising high-quality products. Both companies aim to enhance their global footprint in the cannabis industry, with Yuhan being the first representative of CBD research in Korea's Hemp Free Zone.
